Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
October 2017
-
Media ReleaseNovartis delivered growth on top and bottom line in all divisions in Q3Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew…
-
Media ReleaseNovartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patientsBreakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo1…
-
Media ReleaseNovartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)Nearly 70% of patients maintained platelet counts of >=30×109/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently…
-
Media ReleaseAlcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOLAutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery New Clareon® IOL in vitro data and early clinical experience to…
-
Media ReleaseAlcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congressClareon® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy…
September 2017
-
Media ReleaseNovartis and UC Berkeley collaborate to tackle 'undruggable' disease targetsCollaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and…
-
Media ReleaseNovartis and The Max Foundation transform pioneering cancer access program for people in lower-income countriesCMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has…
-
Media ReleaseNovartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM…
-
Media ReleaseNovartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruptionOPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost…
-
Media ReleaseSandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under…
-
Media ReleaseNovartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety dataCosentyx® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI…
-
Media ReleaseSandoz proposed biosimilar rituximab accepted for review by the FDARituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms…
Pagination
- ‹ Previous page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- …
- 88
- › Next page